Horizon 2020 SME
Dec 2017
Dutch Life Science VCs Swanbridge and Health Innovtions investment helps FABPulous to market

Rotterdam, October 10th, 2017 – Dutch medical start-up FABPulous B.V. welcomed a new round of investment on Tuesday led by Dutch Life Science Venture fund Swanbridge Capital that will help FABPulous bring its H-FABP True Rapid Test® to the commercial market.

With matching investment by Health Innovations Fund II (Utrecht) and supported by existing investors Thuja Capital (Utrecht), Medavinci Development (Amsterdam), LIOF and Limburg Ventures (Maastricht), the new round secures finance needed to take FABPulous to market.

Duko Drijfhout, Fund Manager at Swanbridge joins Chairman Michel Briejer (Thuja) and Dick Sietses (Health Innovations) on the Supervisory Board of FABPulous.

The 5-minute H-FABP True Rapid Test® allows healthcare workers to quickly determine whether a patient with chest pains is at imminent risk of a deadly heart attack by measuring the levels of Heart-Fatty Acid Binding Proteins (H-FABP) in the patient’s blood.

“This latest investment will help FABPulous to begin commercial supply of the H-FABP True Rapid Test® in the next few months,” FABPulous CEO Conor O’Brien said.

Chest pain patients are kept in Emergency Departments and often admitted to hospital overnight until the risk of a heart attack can be excluded. Current tests delay treatment for patients who are at risk of a massive heart attack and clog up hospitals with patients who aren’t.

The H-FABP True Rapid Test® provides doctors with the ability to send those patients to cardiology or home.

“The technology under development within FABPulous shows great promise in quickly ruling out patients from a heart attack” Drijfhout said.

For further information please contact:
Conor O’Brien, Chief Executive Officer – email at c.obrien@fabpulous.com

About FABPulous
FABPulous develops and markets pioneering Point of Care (POC) solutions for better diagnostic tools in primary care and emergency medicine.

About Swanbridge Capital
Swanbridge Capital is a Rotterdam based venture capital fund that actively invests in young, high potential companies in the life sciences.

About Health Innovations Fund
Health Innovations is a Utrecht based fund that invests in technology driven start-ups in healthcare with two funds: Health Innovation Fund I (founded 2007) and Health Innovation Fund II (founded 2012 ).

FABPulous BV 
Marconistraat 16
3029 AK Rotterdam
Netherlands

FABPulous Ltd
St John’s Innovation Centre
Cowley Road, Cambridge
CB4 0WS, UK